BD4P Steering Committee

The BD4P Steering Committee provides strategic guidance on and oversight of BD4P operations. This 12-member multi-stakeholder advisory committee consists of the following representatives:

Voting Members

Academic Representative (1)

  • C. Daniel Mullins, PhD, Professor and Chair, Pharmaceutical Health Research Department, University of Maryland and Executive Director of the University of Maryland’s PATIENTS Program

 Patient Advocate Representatives (4)

 Pharmaceutical Sector Representative (1)

  • Joel W. Beetsch, PhD, Vice President of Global Patient Advocacy, Celgene Corporation

 Technology Sector Representative (1)

  • Ariel Bourla, MD, PhD, Associate Medical Director – Oncology, Flatiron Health

 At Large Representatives (2)

  • Sally Okun, RN, MMHS, Vice President of Advocacy, Policy & Patient Safety, PatientsLikeMe
  • Brad Smith, PhD, Director of Policy, FasterCures

Non-voting Members

PCORI Representative (1)

  • Claudia Grossmann, PhD, Program Officer, Research Infrastructure

 FDA Representative (1)

  • Beth Fritsch, RPh, MBA, Deputy Director, FDA Office of Health and Constituent Affairs (OHCA)

 NIH Representative (1)

  • TBD

RUF Board Liasion Committee

  • TBD
[updated June 16, 2016]